Paul Ellis

TL;DR: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer and outperformed the clinicopathological risk assessment in predicting all endpoints.

TL;DR: The use of genomic grade can identify two clinically distinct ER-positive molecular subtypes in a simple and highly reproducible manner across multiple data sets and emphasizes the important role of proliferation-related genes in predicting prognosis in ER- positive BC.

TL;DR: The phase 3 TNT Trial in subjects with triple-negative breast cancer supports the superiority of carboplatin over docetaxel in BRCA1/2-mutated tumors and a greater response to taxanes in the nonbasal subtype, and concludes that patients with advanced TNBC benefit from characterization of BRC a/2 mutations, but not BRC1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy.

TL;DR: It is unusual to see any such effect on survival so early in an adjuvant breast cancer trial, but trastuzumab is rapidly becoming the standard of care after surgery for high-risk HER2-positive breast cancer.

TL;DR: In the subgroup of patients with stage IIIB LR disease, a strong trend in 2-year survival in favor of L-BLP25 was observed, and maintenance therapy in patients with advanced NSCLC is feasible with minimal toxicity.